Empire Prevent

Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial

[Empire Prevent @EmpirePrevent]

The Empire Prevent trial program marks the first step towards elucidating the potential of SGLT2 inhibition for HF prevention 🫀🫀

Further reading: https://t.co/Cg7MW1K1CP

@CardResearchOuh @HGHHjerte @RigsHeart @jhempelheart @FuchsAndersen @mortschou

[Empire Prevent @EmpirePrevent]

🩷🩵First patient follow-up at Odense University Hospital @CardResearchOuh ☑️🚴‍♀️🫀💊

@EmpirePrevent @FuchsAndersen @mortschou @jhempelheart @RigsHeart @SDCOdense @HGHHjerte

[Empire Prevent @EmpirePrevent]

🩵🩷Empire Prevent on track! 🩵🩷
58% of target population enrolled at @CardReseachOUH & @HGHHjerte
Collaboration with @SDCOdense & @RigsHeart

[Empire Prevent @EmpirePrevent]

Empire Prevent 🩵🩷 includes patients in Odense @CardResearchOuh and Copenhagen @HGHHjerte. We greatly appreciate our collaboration with @SDCOdense and @RigsHeart 🩵🩷

[Empire Prevent @EmpirePrevent]

Patient #100 randomized in Empire Prevent

Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial.

Collaboration between @CardResearchOuh and @HGHHjerte.